Literature DB >> 14996724

A genetically defined model for human ovarian cancer.

Jinsong Liu1, Gong Yang, Jennifer A Thompson-Lanza, Armand Glassman, Kimberly Hayes, Andrea Patterson, Rebecca T Marquez, Nelly Auersperg, Yinhua Yu, William C Hahn, Gordon B Mills, Robert C Bast.   

Abstract

Disruptions of the p53, retinoblastoma (Rb), and RAS signaling pathways and activation of human telomerase reverse transcriptase (hTERT) are common in human ovarian cancer; however, their precise role in ovarian cancer development is not clear. We thus introduced the catalytic subunit of hTERT, the SV40 early genomic region, and the oncogenic alleles of human HRAS or KRAS into human ovarian surface epithelial cells and examined the phenotype and gene expression profile of those cells. Disruption of p53 and Rb pathway by SV40 early genomic region and hTERT immortalized but did not transform the cells. Introduction of HRAS(V12) or KRAS(V12) into the immortalized cells, however, allowed them to form s.c. tumors after injection into immunocompromised mice. Peritoneal injection of the transformed cells produced undifferentiated carcinoma or malignant mixed Mullerian tumor and developed ascites; the tumor cells are focally positive for CA125 and mesothelin. Gene expression profile analysis of transformed cells revealed elevated expression of several cytokines, including interleukin (IL)-1beta, IL-6, and IL-8, that are up-regulated by the nuclear factor-kappaB pathway, which is known to contribute to the tumor growth of naturally ovarian cancer cells. Incubation with antibodies to IL-1beta or IL-8 led to apoptosis in the ras-transformed cells and ovarian cancer cells but not in immortalized cells that had not been transformed. Thus, the transformed human ovarian surface epithelial cells recapitulated many features of natural ovarian cancer including a subtype of ovarian cancer histology, formation of ascites, CA125 expression, and nuclear factor-kappaB-mediated cytokine activation. These cells provide a novel model system to study human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996724     DOI: 10.1158/0008-5472.can-03-3380

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  114 in total

1.  The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.

Authors:  Leo Y Luo; Eejung Kim; Hiu Wing Cheung; Barbara A Weir; Gavin P Dunn; Rhine R Shen; William C Hahn
Journal:  Mol Cancer Res       Date:  2014-11-03       Impact factor: 5.852

2.  RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.

Authors:  Ellen V Stevens; Natalie Banet; Cercina Onesto; Ana Plachco; Jamie K Alan; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Pei Fen Kuan; Jinsong Liu; C Ryan Miller; Dominico Vigil; Lee M Graves; Channing J Der
Journal:  Small GTPases       Date:  2011-07-01

3.  Identification of poly (ADP-ribose) polymerase-1 (PARP-1) as a novel Kruppel-like factor 8-interacting and -regulating protein.

Authors:  Heng Lu; Xianhui Wang; Tianshu Li; Alison M Urvalek; Lin Yu; Jieli Li; Jinghua Zhu; Qishan Lin; Xu Peng; Jihe Zhao
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

4.  Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation.

Authors:  Uddalak Bharadwaj; Christian Marin-Muller; Min Li; Changyi Chen; Qizhi Yao
Journal:  Carcinogenesis       Date:  2011-04-23       Impact factor: 4.944

5.  CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.

Authors:  Gong Yang; Daniel G Rosen; Guangzhi Liu; Fan Yang; Xiaoqing Guo; Xue Xiao; Fengxia Xue; Imelda Mercado-Uribe; Jiaoti Huang; Sue-Hwa Lin; Gordon B Mills; Jinsong Liu
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

6.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

7.  Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications.

Authors:  Weiwei Shan; Imelda Mercado-Uribe; Jing Zhang; Daniel Rosen; Shiwu Zhang; Jianjun Wei; Jinsong Liu
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

8.  Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.

Authors:  Lizhou Jia; Shiwu Zhang; Yanfen Ye; Xin Li; Imelda Mercado-Uribe; Robert C Bast; Jinsong Liu
Journal:  Cancer Lett       Date:  2012-08-15       Impact factor: 8.679

9.  miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.

Authors:  Zhaojian Liu; Elizabeth Gersbach; Xiyu Zhang; Xiaofei Xu; Ruifen Dong; Peng Lee; Jinsong Liu; Beihua Kong; Changshun Shao; Jian-Jun Wei
Journal:  Mol Cancer Res       Date:  2013-09-17       Impact factor: 5.852

10.  Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.

Authors:  Jingfang Zheng; Imelda Mercado-Uribe; Daniel G Rosen; Bin Chang; Peishu Liu; Gong Yang; Anais Malpica; Honami Naora; Nelly Auersperg; Gordon B Mills; Robert C Bast; Jinsong Liu
Journal:  Cell Cycle       Date:  2010-01-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.